BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vaxman I, Gertz M. Risk adapted post-transplant maintenance in multiple myeloma. Expert Rev Hematol 2019;12:107-18. [PMID: 30696304 DOI: 10.1080/17474086.2019.1576521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG). Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J 2021;11:1. [PMID: 33414374 DOI: 10.1038/s41408-020-00390-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bird SA, Jackson GH, Pawlyn C. Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clin Hematol Int 2020;2:59-68. [PMID: 34595444 DOI: 10.2991/chi.d.200502.001] [Reference Citation Analysis]